Carregant...
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR-T cells
Immunotherapy with chimeric antigen receptor (CAR)-engineered T cells can be effective against advanced malignancies. CAR-T cells are ‘living drugs’ that require technologies to enable physicians (and patients) to maintain control over the infused cell product. Here, we demonstrate that the tyrosine...
Guardat en:
| Publicat a: | Sci Transl Med |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523030/ https://ncbi.nlm.nih.gov/pubmed/31270272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aau5907 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|